Dual hepatitis virus infections in liver transplant: Case report and a review of the literature

Maria L. Yataco, Rolland C. Dickson, Hugo Bonatti, Jaime Aranda-Michel, Julio Mendez, Marwan Ghabril, Justin Nguyen

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Background: Liver transplantation (LT) using grafts from anti-HBVcore antibody-positive (anti-HBVcAB+) donors carry risk for development of hepatitis B virus (HBV) infection. The long-term course of hepatitis C virus (HCV) patients receiving anti-HBVcAB+ grafts is poorly understood. Patients and methods: A patient with chronic hepatitis C received an anti-HBVc+ graft and developed de novo hepatitis B after four months. We describe the 14 HCV patients who received antiHBVc+ grafts and the condition of disease. Results: Hepatitis B was treated successfully with lamivudine. One year later, breakthrough infection developed with a lamivudine-resistant mutant. Addition of adefovir led to HBV surface antigen to surface antibody seroconversion after twoyr, which was maintained long term. Antiviral therapy was discontinued. Liver biopsy revealed minimal histologic changes up to eightyr post-LT. Survival of 14 recipients of antiHBVc+ allografts and 180 recipients of antiHBVc-negative grafts was equal (minimum follow up of fiveyr). Liver biopsies at fouryr showed grade 0/1 and stage 0/1 in >70% only two patients showed bridging fibrosis. A literature review of dual hepatitis virus infection revealed an overall milder course of hepatitis post-LT. Conclusion: The outcome of HCV patients receiving anti-HBc+ grafts is good and may be associated with a milder course of recurrent HCV.

Original languageEnglish (US)
Pages (from-to)282-288
Number of pages7
JournalClinical Transplantation
Volume23
Issue number2
DOIs
StatePublished - 2009
Externally publishedYes

Fingerprint

Hepatitis Viruses
Virus Diseases
Transplants
Hepacivirus
Liver
Liver Transplantation
Lamivudine
Hepatitis B
Hepatitis B virus
Biopsy
Chronic Hepatitis C
Hepatitis B Surface Antigens
Hepatitis
Antiviral Agents
Allografts
Anti-Idiotypic Antibodies
Fibrosis
Tissue Donors
Survival
Antibodies

Keywords

  • Hepatitis B
  • Hepatitis B core antibody donor
  • Hepatitis C
  • Liver transplantation

ASJC Scopus subject areas

  • Transplantation

Cite this

Dual hepatitis virus infections in liver transplant : Case report and a review of the literature. / Yataco, Maria L.; Dickson, Rolland C.; Bonatti, Hugo; Aranda-Michel, Jaime; Mendez, Julio; Ghabril, Marwan; Nguyen, Justin.

In: Clinical Transplantation, Vol. 23, No. 2, 2009, p. 282-288.

Research output: Contribution to journalArticle

Yataco, Maria L. ; Dickson, Rolland C. ; Bonatti, Hugo ; Aranda-Michel, Jaime ; Mendez, Julio ; Ghabril, Marwan ; Nguyen, Justin. / Dual hepatitis virus infections in liver transplant : Case report and a review of the literature. In: Clinical Transplantation. 2009 ; Vol. 23, No. 2. pp. 282-288.
@article{e22d69f3f2124a30a2b97d0c295e48fe,
title = "Dual hepatitis virus infections in liver transplant: Case report and a review of the literature",
abstract = "Background: Liver transplantation (LT) using grafts from anti-HBVcore antibody-positive (anti-HBVcAB+) donors carry risk for development of hepatitis B virus (HBV) infection. The long-term course of hepatitis C virus (HCV) patients receiving anti-HBVcAB+ grafts is poorly understood. Patients and methods: A patient with chronic hepatitis C received an anti-HBVc+ graft and developed de novo hepatitis B after four months. We describe the 14 HCV patients who received antiHBVc+ grafts and the condition of disease. Results: Hepatitis B was treated successfully with lamivudine. One year later, breakthrough infection developed with a lamivudine-resistant mutant. Addition of adefovir led to HBV surface antigen to surface antibody seroconversion after twoyr, which was maintained long term. Antiviral therapy was discontinued. Liver biopsy revealed minimal histologic changes up to eightyr post-LT. Survival of 14 recipients of antiHBVc+ allografts and 180 recipients of antiHBVc-negative grafts was equal (minimum follow up of fiveyr). Liver biopsies at fouryr showed grade 0/1 and stage 0/1 in >70{\%} only two patients showed bridging fibrosis. A literature review of dual hepatitis virus infection revealed an overall milder course of hepatitis post-LT. Conclusion: The outcome of HCV patients receiving anti-HBc+ grafts is good and may be associated with a milder course of recurrent HCV.",
keywords = "Hepatitis B, Hepatitis B core antibody donor, Hepatitis C, Liver transplantation",
author = "Yataco, {Maria L.} and Dickson, {Rolland C.} and Hugo Bonatti and Jaime Aranda-Michel and Julio Mendez and Marwan Ghabril and Justin Nguyen",
year = "2009",
doi = "10.1111/j.1399-0012.2008.00929.x",
language = "English (US)",
volume = "23",
pages = "282--288",
journal = "Clinical Transplantation",
issn = "0902-0063",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Dual hepatitis virus infections in liver transplant

T2 - Case report and a review of the literature

AU - Yataco, Maria L.

AU - Dickson, Rolland C.

AU - Bonatti, Hugo

AU - Aranda-Michel, Jaime

AU - Mendez, Julio

AU - Ghabril, Marwan

AU - Nguyen, Justin

PY - 2009

Y1 - 2009

N2 - Background: Liver transplantation (LT) using grafts from anti-HBVcore antibody-positive (anti-HBVcAB+) donors carry risk for development of hepatitis B virus (HBV) infection. The long-term course of hepatitis C virus (HCV) patients receiving anti-HBVcAB+ grafts is poorly understood. Patients and methods: A patient with chronic hepatitis C received an anti-HBVc+ graft and developed de novo hepatitis B after four months. We describe the 14 HCV patients who received antiHBVc+ grafts and the condition of disease. Results: Hepatitis B was treated successfully with lamivudine. One year later, breakthrough infection developed with a lamivudine-resistant mutant. Addition of adefovir led to HBV surface antigen to surface antibody seroconversion after twoyr, which was maintained long term. Antiviral therapy was discontinued. Liver biopsy revealed minimal histologic changes up to eightyr post-LT. Survival of 14 recipients of antiHBVc+ allografts and 180 recipients of antiHBVc-negative grafts was equal (minimum follow up of fiveyr). Liver biopsies at fouryr showed grade 0/1 and stage 0/1 in >70% only two patients showed bridging fibrosis. A literature review of dual hepatitis virus infection revealed an overall milder course of hepatitis post-LT. Conclusion: The outcome of HCV patients receiving anti-HBc+ grafts is good and may be associated with a milder course of recurrent HCV.

AB - Background: Liver transplantation (LT) using grafts from anti-HBVcore antibody-positive (anti-HBVcAB+) donors carry risk for development of hepatitis B virus (HBV) infection. The long-term course of hepatitis C virus (HCV) patients receiving anti-HBVcAB+ grafts is poorly understood. Patients and methods: A patient with chronic hepatitis C received an anti-HBVc+ graft and developed de novo hepatitis B after four months. We describe the 14 HCV patients who received antiHBVc+ grafts and the condition of disease. Results: Hepatitis B was treated successfully with lamivudine. One year later, breakthrough infection developed with a lamivudine-resistant mutant. Addition of adefovir led to HBV surface antigen to surface antibody seroconversion after twoyr, which was maintained long term. Antiviral therapy was discontinued. Liver biopsy revealed minimal histologic changes up to eightyr post-LT. Survival of 14 recipients of antiHBVc+ allografts and 180 recipients of antiHBVc-negative grafts was equal (minimum follow up of fiveyr). Liver biopsies at fouryr showed grade 0/1 and stage 0/1 in >70% only two patients showed bridging fibrosis. A literature review of dual hepatitis virus infection revealed an overall milder course of hepatitis post-LT. Conclusion: The outcome of HCV patients receiving anti-HBc+ grafts is good and may be associated with a milder course of recurrent HCV.

KW - Hepatitis B

KW - Hepatitis B core antibody donor

KW - Hepatitis C

KW - Liver transplantation

UR - http://www.scopus.com/inward/record.url?scp=64349111703&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64349111703&partnerID=8YFLogxK

U2 - 10.1111/j.1399-0012.2008.00929.x

DO - 10.1111/j.1399-0012.2008.00929.x

M3 - Article

C2 - 19191801

AN - SCOPUS:64349111703

VL - 23

SP - 282

EP - 288

JO - Clinical Transplantation

JF - Clinical Transplantation

SN - 0902-0063

IS - 2

ER -